IBRX Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Immunitybio Inc

Watchlist Manager

Watchlist

Price: 7.1 USD -4.05% Market Closed

Market Cap: $7.4B

	Immunitybio Inc NASDAQ:IBRX	US
G	Genpact Ltd SWB:35G	BM
S	SFC Energy AG DUS:F3C	DE
T	Talanx AG F:TLX	DE
G	Gentex Corp F:GTX	US

Profitability Summary

Immunitybio Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

99%

Sustainable 3Y Average Gross Margin

47%

Negative Operating Margin

-185%

Negative 3Y Average Operating Margin

-28 223%

Operating Margin is Increasing

-63 124% > -185%

Negative Net Margin

-606%

Negative 3Y Average Net Margin

-43 036%

Net Margin is Increasing

-80 234% > -606%

Negative Free Cash Flow Margin

-212%

Negative 3Y Average Free Cash Flow Margin

-31 673%

Free Cash Flow Margin is Increasing

-65 631% > -212%

Exceptional ROE

117%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-144%

ROIC is Increasing

-171% > -108%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.